Hepatitis C Virus Infection Pipeline Landscape Analysis of 20+ Companies by DelveInsight

October 12 03:29 2022
Hepatitis C Virus Infection Pipeline Landscape Analysis of 20+ Companies by DelveInsight

DelveInsight’s, “Hepatitis C Virus Infection Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hepatitis C Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Hepatitis C Virus Infection Pipeline Report

  • DelveInsight’s Hepatitis C Virus Infection Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Hepatitis C Virus Infection treatment.
  • The leading Hepatitis C Virus Infection companies such as Dongguan HEC TaiGen Biopharmaceuticals, Nanjing Sanhome Pharmaceutical, PharmaEssentia, HEC Pharm, Atea Pharmaceuticals, AllaChem, HepC, Sunshine Lake Pharma, GeneCure Biotechnologies, Therapure Innovations, Adaptimmune, Orgenesis, Dekk-Tec, and others are developing potential drug candidates to improve the Hepatitis C Virus Infection treatment scenario.
  • The promising Hepatitis C Virus Infection therapies in the pipeline included such as MP-424 (Telaprevir), Avaxim 80U, Havrix 720 Junior, and others.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis C Virus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis C Virus Infection.

 

Get an overview of the pipeline landscape @ Hepatitis C Virus Infection Pipeline Outlook

 

Hepatitis C Virus Infection Overview

Hepatitis C Virus Infection is a liver infection caused by the Hepatitis C Virus Infection virus. Hepatitis C Virus Infection can range from a mild illness lasting a few weeks to a serious, long-term illness. The Hepatitis C Virus Infection virus (HCV) spreads through contaminated blood. The Hepatitis C Virus Infection virus is a blood borne virus, the most common modes of infection are through exposure to small quantities of blood. This may happen through injection drug use, unsafe injection practices, unsafe health care, transfusion of unscreened blood and blood products, and sexual practices that lead to exposure to blood.

Hepatitis C Virus Infection is often described as “acute,” meaning a new infection, or “chronic,” meaning long-term infection. Chronic Hepatitis C Virus Infection can be a serious disease resulting in long-term health problems, including liver damage, liver failure, cirrhosis, liver cancer, and even death. Symptoms may include fever, fatigue, decreased appetite, nausea, vomiting, abdominal pain, dark urine, grey-colored faeces, joint pain and jaundice (yellowing of skin and the whites of the eyes). Treatments for Hepatitis C Virus Infection includes antivirals, like medications called direct-acting antivirals (DAAs) work to fully remove the Hepatitis C Virus Infection virus from the body while helping prevent liver damage.

 

Latest Breakthroughs and Developments in the Hepatitis C Virus Infection Treatment Landscape

  • TG-2349 (Furaprevir) is a HCV protease inhibitor. It is a novel direct acting antivirals for the all-oral treatment of chronic Hepatitis C Virus Infection virus (HCV) infection. The drug has completed Phase III clinical evaluation in combination with DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected patients.
  • SH229 is a NS5B inhibitor that is being developed by Nanjing Sanhome Pharmaceutical for the treatment of chronic Hepatitis C Virus Infection virus infection. The drug is currently in Phase II/III clinical studies combined with fixed-dose Daclatasvi dihydrochloride (DCV) tablets for the treatment of Hepatitis C Virus Infection virus infection.

 

Hepatitis C Virus Infection Emerging Drugs

  • TG-2349: Dongguan HEC TaiGen Biopharmaceuticals
  • SH229: Nanjing Sanhome Pharmaceutical

 

Hepatitis C Virus Infection Pipeline Therapeutics Analysis

There are approx. 20+ key companies which are developing the therapies for Hepatitis C Virus Infection. The companies which have their Hepatitis C Virus Infection drug candidates in the most advanced stage, i.e. Phase III include, Dongguan HEC TaiGen Biopharmaceuticals.

 

DelveInsight’s Hepatitis C Virus Infection Pipeline Report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

For further information, refer to the detailed report @ Hepatitis C Virus Infection Emerging Therapies

 

Scope of the Hepatitis C Virus Infection Pipeline Report

  • Coverage- Global
  • Hepatitis C Virus Infection Companies- Dongguan HEC TaiGen Biopharmaceuticals, Nanjing Sanhome Pharmaceutical, PharmaEssentia, HEC Pharm, Atea Pharmaceuticals, AllaChem, HepC, Sunshine Lake Pharma, GeneCure Biotechnologies, Therapure Innovations, Adaptimmune, Orgenesis, Dekk-Tec, and others.
  • Hepatitis C Virus Infection Therapies- MP-424 (Telaprevir), Avaxim 80U, Havrix 720 Junior, and others
  • Hepatitis C Virus Infection Therapeutic Assessment by Product Type
  • Hepatitis C Virus Infection Therapeutic Assessment by Stage and Product Type
  • Hepatitis C Virus Infection Therapeutic Assessment by Route of Administration
  • Hepatitis C Virus Infection Therapeutic Assessment by Stage and Route of Administration
  • Hepatitis C Virus Infection Therapeutic Assessment by Molecule Type
  • Hepatitis C Virus Infection Therapeutic Assessment by Stage and Molecule Type
  • Hepatitis C Virus Infection companies’ collaborations, Licensing, Acquisition -Deal Value Trends

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hepatitis C Virus Infection: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. TG-2349: Dongguan HEC TaiGen Biopharmaceuticals
  8. Mid Stage Products (Phase II)
  9. AT 527: Atea Pharmaceuticals
  10. Early Stage Products (Phase I)
  11. HEC 74647PA: Sunshine Lake Pharma
  12. Preclinical and Discovery Stage Products
  13. Prophylactic HCV vaccine: GeneCure Biotechnologies
  14. Inactive Products
  15. Hepatitis C Virus Infection Key Companies
  16. Hepatitis C Virus Infection Key Products
  17. Hepatitis C Virus Infection- Unmet Needs
  18. Hepatitis C Virus Infection- Market Drivers and Barriers
  19. Hepatitis C Virus Infection- Future Perspectives and Conclusion
  20. Hepatitis C Virus Infection Analyst Views
  21. Hepatitis C Virus Infection Key Companies
  22. Appendix

 

Got Queries? Reach out for more information on the Hepatitis C Virus Infection Pipeline Report- Hepatitis C Virus Infection Pipeline Therapeutic Assessment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/